$414 Million is the total value of New Leaf Venture Partners, L.L.C.'s 15 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was 64.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| DCPH | DECIPHERA PHARMACEUTICALS INC | $161,498,000 | +96.4% | 4,104,140 | 0.0% | 38.98% | -12.2% | |
| APTX | New | APTINYX INC | $79,521,000 | – | 3,290,079 | +100.0% | 19.19% | – |
| STIM | New | NEURONETICS INC | $41,062,000 | – | 1,543,115 | +100.0% | 9.91% | – |
| CRSP | Sell | CRISPR THERAPEUTICS AGnamen akt | $26,131,000 | -4.0% | 444,708 | -25.3% | 6.31% | -57.1% |
| UMRX | Buy | UNUM THERAPEUTICS INC | $25,766,000 | +321.6% | 1,795,545 | +226.5% | 6.22% | +88.5% |
| WVE | Sell | WAVE LIFE SCIENCES LTD | $16,579,000 | -9.8% | 433,429 | -5.4% | 4.00% | -59.7% |
| ITRM | New | ITERUM THERAPEUTICS PLC | $15,539,000 | – | 1,456,303 | +100.0% | 3.75% | – |
| SRRA | SIERRA ONCOLOGY INC | $14,861,000 | +43.0% | 5,020,446 | 0.0% | 3.59% | -36.1% | |
| OBSV | OBSEVA SA | $13,482,000 | +12.2% | 890,501 | 0.0% | 3.25% | -49.9% | |
| VSAR | New | VERSARTIS INC | $4,550,000 | – | 2,247,000 | +100.0% | 1.10% | – |
| AVRO | New | AVROBIO INC | $4,284,000 | – | 150,000 | +100.0% | 1.03% | – |
| OXFD | Sell | OXFORD IMMUNOTEC GLOBAL PLC | $4,017,000 | -62.2% | 311,660 | -63.4% | 0.97% | -83.1% |
| AFMD | AFFIMED N V | $3,713,000 | -10.8% | 2,250,000 | 0.0% | 0.90% | -60.1% | |
| EDGE | EDGE THERAPEUTICS INC | $2,415,000 | -12.7% | 2,344,868 | 0.0% | 0.58% | -61.0% | |
| AVEO | Sell | AVEO PHARMACEUTICALS INC | $909,000 | -67.5% | 402,118 | -58.3% | 0.22% | -85.5% |
| DERM | Exit | DERMIRA INC | $0 | – | -61,109 | -100.0% | -0.26% | – |
| MRNS | Exit | MARINUS PHARMACEUTICALS INC | $0 | – | -342,550 | -100.0% | -0.71% | – |
| Exit | TRILLIUM THERAPEUTICS INC | $0 | – | -404,159 | -100.0% | -1.57% | – | |
| RSLS | Exit | RESHAPE LIFESCIENCES INC | $0 | – | -2,600,900 | -100.0% | -2.04% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| DECIPHERA THERAPEUTICS INC | 25 | Q3 2023 | 44.4% |
| CHIMERIX INC | 25 | Q1 2023 | 20.9% |
| SIERRA ONCOLOGY INC | 22 | Q2 2022 | 14.9% |
| ARVINAS INC | 21 | Q3 2023 | 44.8% |
| CRINETICS PHARMACEUTICALS INC | 21 | Q3 2023 | 11.4% |
| OBSEVA SA | 20 | Q4 2021 | 8.5% |
| AVROBIO INC | 20 | Q1 2023 | 1.7% |
| HARPOON THERAPEUTICS INC | 19 | Q3 2023 | 20.0% |
| ALECTOR INC | 19 | Q3 2023 | 4.6% |
| ITERUM THERAPEUTICS PLC | 18 | Q3 2022 | 3.8% |
View New Leaf Venture Partners, L.L.C.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-10 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-06 |
| 13F-HR | 2022-11-10 |
| 13F-HR | 2022-08-09 |
| 13F-HR | 2022-05-06 |
| 13F-HR | 2022-02-11 |
| 13F-HR | 2021-11-12 |
View New Leaf Venture Partners, L.L.C.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.